As the race to develop targeted therapies continues, pharmaceutical companies seek to create a competitive advantage by developing new treatments for actionable biomarkers.

The clinical trial's success is strongly dependent on a company's ability to recruit eligible patients with a higher predictive responsiveness factor.

It is estimated that up to 80% of clinical trials fail to meet enrollment timelines, while 26% of rare diseases trials are terminated because of low accrual rates

lmagene is pharma's first choice for an optimized drug development, clinical trials design and enrollment,
and molecular profiling solutions